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Abstract: 
Objective: 
Access to care is key to effective rectal cancer treatment.  We hypothesized that ethnic/racial 
minorities living in high population density areas would have the greatest delays in cancer care 
compared to whites living in medium population density areas. 
 
Methods: 
Using 2004-2016 National Cancer DataBase data, we identified stage I-III patients with invasive 
rectal adenocarcinoma who underwent surgery.  The data were analyzed by race/ethnicity 
(whites, blacks, or Hispanics) and population density (metropolitan or urban/rural).  
Multivariable ANCOVA was performed to evaluate the duration of time from diagnosis to 
surgery.  
 
Results: 
The study population consisted of 76,131 patients: 65,172 Non-Hispanic whites (NHW; 85.6%), 
6,167 Non-Hispanic blacks (NHB; 8.1%), and 4,792 Hispanics (6.3%). Of these, 61,363 patients 
(80.6%) lived in metropolitan areas.  
 
Among direct-to-surgery patients, the greatest difference in mean time from diagnosis to surgery 
was 20.3 days (urban/rural NHW, 53.3 days, vs. metropolitan Hispanics, 73.6 days).  Among 
patients receiving neoadjuvant therapy, the greatest difference in mean time from diagnosis to 
surgery was 18.8 days (urban/rural NHW, 136.9 days, vs. metropolitan NHB, 155.7 days).  
 
   v
After multivariable adjustment for several socioeconomic and clinical factors, among direct-to-
surgery patients, metropolitan Hispanics had a 16.5-day delay (95% CI 12.9-20.0) compared 
with urban/rural NHW.  In patients receiving neoadjuvant therapy, metropolitan NHB had an 
18.1-day delay (95% CI 16.1-20.0) compared to urban/rural NHW. 
 
Conclusion: 
The combination of high population density and racial/ethnic minority status was associated with 
delays in rectal cancer care that persisted after adjusting for other important factors. 
Understanding which populations are at risk and perceived obstacles to timely care will help 
inform interventions to minimize treatment access disparities. 
 
Key Words: 
Rectal Cancer; Access to Care; Healthcare Disparities 
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Chapter 1: Introduction 
Rectal Cancer 
Colorectal cancer is the third most common malignancy diagnosed and the fourth leading 
cause of cancer-related deaths both worldwide1 and in the United States.2  The American Cancer 
Society has estimated that there will be 104,610 cases of newly diagnosed colon cancer and 
43,340 new cases of rectal cancer in the U.S. in 2020.  There are multiple histologic subtypes of 
colorectal cancer: adenocarcinoma, carcinoid and other neuroendocrine tumors, gastrointestinal 
stromal tumor, lymphomas, hamartomas, and mesenchymal tumors.  Of these, over 90% exhibit 
adenocarcinoma histology.3   
Based on the Surveillance, Epidemiology, and End Results (SEER) data, the American 
Cancer Society estimates that patients with rectal cancer have an average 5-year survival rate of 
67% for all stages combined. 2  After stratification by disease stage, the 5-year relative survival 
rate was estimated at 90% for localized disease, 71% for regional disease, and 14% for distant 
disease.   
The treatment of rectal cancer is highly complex due to imaging limitations, technical 
demands of the surgery, and multiple treatment paradigms.  The current imaging technology has 
diagnostic limitations; magnetic resonance imaging, currently the standard of care per the 
National Comprehensive Cancer Network guidelines,4 has only a 75% sensitivity for T stage and 
71% sensitivity for nodal metastases.5  This creates the potential for under-staging and 
undertreatment. of patients with potential rectal cancer.  From the surgical perspective, total 
mesorectal excision, the gold standard for adequate local control, is technically difficult due to 
the physical constraints of the bony pelvis, several nearby key urogenital structures, and 
challenging dissection planes.  Moreover, treatment is multifaceted with many key decision 
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points including whether a patient would benefit from neoadjuvant and/or adjuvant 
chemoradiation, which therapeutic regimen to use, and which surgery to perform accounting for 
tumor characteristics, location, and patient comorbidities.  As such, multidisciplinary tumor 
boards are essential to maximizing the quality of care a patient receives and should involve 
physicians from surgery, medical oncology, radiation oncology, and radiology.  Given the high 
level of complexity involved in rectal cancer care, there are multiple pathways through which 
potential disparities may arise. 
Currently available data have shown considerable variability in long-term outcomes of 
patients with rectal cancer with these rates influenced by factors including hospital volume and 
compliance with standards of care.  Higher-volume surgeons and hospitals have been associated 
with higher rates of total mesorectal excision, improved lymph node harvest, decreased 
colostomy rates, and decreased local recurrence.6-8  To standardize rectal cancer practices, 
multiple European countries have implemented policies with the Norwegian Rectal Cancer 
Project,9 Spanish Rectal Cancer Project,10 and Dutch Colorectal Cancer Group.11  All of these 
programs have shown significant improvements in rates of total mesorectal excisions.  In the 
United States, the National Accreditation Program for Rectal Cancer was created in 2017 
through “a collaboration between The OSTRiCh Consortium and the Commission on Cancer, a 
quality program of the American College of Surgeons” to address these challenges and promote 
standardization of practices and quality improvement.12  While a key step towards improving 
rectal cancer quality, only fifteen sites have been accredited as of April 2020,13 reaching a small 
proportion of patients with rectal cancer in limited centers. 
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Socioeconomic Disparities in Cancer Care and Outcomes 
Disparities exist between racial and ethnic groups in terms of the magnitude and 
prognosis associated with colorectal cancer.  A previous SEER study using 1985-2008 data 
showed increased mortality in blacks at every stage of colorectal cancer, with the largest survival 
differences (a 1.72 black:white mortality rate ratio) among those with distant stage of disease.14  
The authors speculated that this could be related to differences in early detection and treatment 
with decreased screening15 and uneven dissemination of adjuvant chemotherapy for Stage II and 
III colorectal cancer in black populations.8, 16  A study using National Cancer Database (NCDB) 
1998-2006 data, with propensity matching for clinically significant variables, found that blacks 
were more likely to present with higher stage rectal cancer.17  Among patients with resectable 
stage I-III disease, blacks underwent surgery less frequently than whites (78% vs. 86%), and, 
even among those who underwent resection, black race was still associated with 20% higher risk 
of 5-year mortality compared with whites after propensity matching for key clinical and 
socioeconomic variables. 
Access to care differences also exist along population density gradients.  A rectal cancer 
study examining 2007-2011 SEER patients found that those living in rural areas were more 
likely to have their surgeries done by low volume surgeons at low volume hospitals, have a 
general surgeon compared to a colorectal surgery specialist, and have higher drive times to the 
hospital.18   A NCDB study using 2006-2014 data found that patients with rectal cancer living in 
rural areas had a 42% higher odds of undertreatment with neoadjuvant radiation compared to 
those living in metropolitan areas.19   A study on patient ratings of access to care using 1998-
2013 SEER-Consumer Assessment of Healthcare Providers & Systems data found non-Hispanic 
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black and Hispanic breast, lung, and colorectal cancer patients in rural areas rated “getting need 
care” lower than those living in urban areas.20 
 
Overview of the National Cancer Database (NCDB) 
The NCDB was created in 1989 and is jointly sponsored by the American Cancer Society 
and the Commission on Cancer of the American College of Surgeons.21  This database contains 
de-identified data from over 1,500 hospitals that hold Commission on Cancer accreditation, 
representing approximately 70% of all newly diagnosed cases of cancer in the United States  It is 
important to note that the NCDB is hospital-based and not population-based data.  All data 
collection is sourced from hospital cancer registries by certified tumor registrars with over 34 
million records in total.  
 To maintain accreditation, programs are mandated to access, abstract, and conduct 
follow-up activities for all required tumors diagnosed and/or treated at the abstracting facility.  
Data have standardized coding definitions based on the Standards for Oncology Registry Entry 
guidebook22 (the most recent revision in 2018 reflects the American Joint Committee on Cancer 
8th edition staging standards).  In addition, there are over 600 automated edit checks and regular 
audits to ensure data fidelity.  Data access is granted only to participants at Commission on 
Cancer hospital sites after submission of an application that is reviewed by NCDB staff on a bi-
annual basis.   
Compared with SEER, this database has more granularity regarding diagnosis and 
treatment variables such as timing and type of surgery, chemotherapy, and radiation.  The  
Commission on Cancer hospitals are the source of the de-identified data used herein; they have 
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not been verified and are not responsible for the statistical validity of the data analysis or the 
conclusions derived by the authors. 
 
Specific Aims 
The primary aim of this retrospective study was to examine, among patients with newly 
diagnosed rectal cancer, if racial/ethnic minority status and living in metropolitan areas was 
associated with delays in access to care.  The secondary aims of the study were to evaluate 
differences in short-term outcomes (30-day readmission and 30-day and 90-day mortality) 
according to racial/ethnic minority status and population density groups.  This study utilized the 
NCDB data from 2004-2016 on patients with stage I-III rectal adenocarcinoma to examine these 
outcomes. Patients with metastatic cancer were excluded because the complex evaluation and 
timing of potential metastectomy is impossible to evaluate from a retrospective database but this 
cohort would likely have different timing to definitive resection.    
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Chapter 2: Methods 
Data Source 
Using the NCDB, we initially performed a cross-sectional analysis after combining all 
cases of patients with rectal cancer diagnosed from January 1, 2004 to December 31, 2016. 
 
Case Selection 
 Patients were included in the study if they had adenocarcinoma histology (ICD-O-3 814, 
821, 826, 848, 859), invasive behavior only, and underwent a proctectomy (partial proctectomy, 
pull through with sphincter preservation, total proctectomy, or proctectomy not otherwise 
specified).  
 Patients were excluded if they were clinical stage IV because the NCDB does not clearly 
delineate extent of metastatic disease beyond location, so it is difficult to tell who is a candidate 
for metastectomy.  Furthermore, even if the patient is a candidate, the timing is highly complex 
with no clear standard of care for whether this should occur prior, simultaneous to, or following 
primary disease resection, which would affect the primary outcome of interest.  In addition, 
patients were excluded if they were involved in clinical trials because there could be 
unconventional timing as they were no longer receiving standard of care therapy.   In addition, 
patients were excluded if they were missing data on the following key variables: clinical stage, 
exposure variables of interest (race, ethnicity, and county population density), or neoadjuvant 
chemotherapy or radiation status.  Finally, patients were excluded if they underwent non-
proctectomy surgeries to create a more homogenous patient population.  The local tumor 
destruction/excision code could include either polypectomies, which may be oncologically 
insufficient resection, or transanal endoscopic microsurgery, but this level of detail cannot be 
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determined in this database.  In addition, patients who underwent more radical procedures (total 
proctocolectomy or pelvic exenteration) likely reflected more aggressive locoregional disease 
that may not be a true stage I-III patient if there was concern for invasion into adjacent structures 
or other underlying disease pathology necessitating a more aggressive than standard-of-care 
oncologic procedure.  
 
Independent and Dependent Variables 
 Race and ethnicity are both highly complex social constructs that have multifaceted 
components and a single person may possess multiple racial/ethnic identities.  For purposes of 
this study, which seeks primarily to clarify disparities that may be driven by “minority” status, 
race and ethnicity have been simplified for analysis.  NCDB defines their race variable to be 
analyzed with their Spanish/Hispanic origin variable and both items must be recorded.  Patients 
are identified by the “primary race of the person.”  Spanish/Hispanic origin is defined by the 
NCDB to be those of Spanish/Hispanic origin of any race.  Patients were stratified based on 
race/ethnicity groups into three mutually exclusive categories: Non-Hispanic whites (NHW), 
Non-Hispanic blacks (NHB), and Hispanics. Patients that did not fall into one of these three 
categories were excluded from analysis due to small sample sizes. 
 The second key exposure of interest was metropolitan vs. urban/rural status.  NCDB 
determines population density status by matching state and county Federal Information 
Processing Standard codes of the patient recorded at the time of diagnosis against the 2013 files 
published by the United States of Department of Agriculture Economic Research Service.23  
Population density was analyzed as either metropolitan (at least 250,000 population), urban 
(2,500-20,000 or more adjacent to a metropolitan area), and rural (<2,500 population either 
   8
adjacent or non-adjacent to a metropolitan area).  To simultaneously examine the effects of 
population density and minority status, and because certain cells for rural patients were less than 
10, which violates the NCDB data use agreement, urban and rural were combined for purposes 
of this analysis. 
 Other patient sociodemographic characteristics examined included age (all patients 90 or 
older are censored as 90 to protect against potential identification), year of diagnosis (divided 
into three roughly equivalent categories for analysis), and sex.  Insurance status was recorded by 
NCDB as the primary payor and was categorized for analysis as private, government (including 
Medicaid, Medicare, and other government), none, or unknown.  Both education and income 
data were defined by census-tract level data by matching the zip code of the patient at the time of 
diagnosis against files derived from the 2016 American Community Survey data and categorized 
into equally portioned quartiles among all United States zip codes.  Educational attainment was 
measured as  the percentage of adults 25 years and older who did not graduate from high school.  
Median household income was adjusted for 2016 inflation.  Both education and income were 
analyzed dichotomously (lowest quartile vs. top three quartiles).  Distance from residence to 
treatment facility is recorded by NCDB based on the centroid of the patient’s zip code and street 
address of the hospital facility.  For analysis, this was divided into three groups based on 
previously published NCDB literature24 as <10 miles, 10-49 miles, >50 miles.   
 Three facility variables were used in the present analysis.  Facility type was assigned by 
the Commission on Cancer Accreditation program25 as Community Cancer Program, 
Comprehensive Community Cancer Program, Academic/Research Program including National 
Cancer Institute-designated comprehensive cancer centers, or Integrated Network Cancer 
Programs.  Facility location was categorized by census regions:26 Northeast (New England, 
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Middle Atlantic), South (South Atlantic, East South Central, West South Central), Midwest (East 
North Central, West North Central), and West (Mountain, Pacific).  A facility volume variable 
was created using facility identification codes and number of incident cases to divide this 
variable into tertiles.  To account for potential yearly variance, the total number of cases was 
summed over the most recent 5 years of the database (i.e., 2011- 2016 data).  The facilities were 
divided into high (29-412 cases / 5 years), medium (12 – 28), and low (1 – 11) volume.   
 Clinical comorbidity was evaluated in NCDB with the Charlson-Deyo score,27 which is a 
well-validated research tool that is a composite score of ten equally-weighted diagnoses 
(myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular 
disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild 
liver disease, diabetes, diabetes with chronic complications, hemiplegia or paraplegia, renal 
disease, moderate or severe liver disease, and AIDS).  This was then recorded in the database as 
a value of 0, 1, 2, and 3 or more. 
 Clinical stage grouping was defined based on the Cancer Staging Manual published by 
the American Joint Committee on Cancer.  These designations were determined based on a 
patient’s T, N, and M (depth of invasion, nodal involvement, metastatic disease, respectively) 
status, which were required by NCDB standards to be copied from a standardized document 
found in the record that was recorded by the managing physician.  These were analyzed as stage 
I, II, or III rectal cancer. 
 Order of treatment was determined using the NCDB Systemic Surgery Sequence and 
Radiation Surgery Sequence variables.  Neoadjuvant treatment was defined by receipt of both 
systemic chemotherapy and radiation prior to surgery as this is the standard of care per NCCN 
   10
guidelines for stage II and III rectal cancer patients.4  Patients who did not receive neoadjuvant 
therapy were treated as the direct-to-surgery group. 
 
Statistical Analysis 
 All univariate comparisons were done between the three racial/ethnic groups.  
Continuous variables are shown as means with standard deviations and tested for significance 
with ANOVA.  Categorical variables are shown as frequencies and tested for significance with 
the chi square test. 
 Using the three race/ethnicity designations (NHB, NHW, vs. Hispanic) and the two 
population density designations (metropolitan vs. urban/rural), six different combinations were 
created to compare patients from these groups in the analysis for the primary outcome of timing 
from diagnosis to definitive surgery.  Two separate univariate ANOVA models were used to 
evaluate the association between race/ethnicity-population density group and time to definitive 
surgery among patients who: (1) received neoadjuvant treatment or (2) were direct-to-surgery.  
The reference group was chosen based on which race/ethnicity-population density group had the 
shortest time interval.  These ANOVA models were also evaluated using an interaction term 
between for race/ethnicity group and population density.  Results are reported as beta coefficient 
(95% confidence interval, 95% CI).  Two separate ANCOVA models were fit using backwards 
stepwise selection based on variables that were different at p < 0.20 on univariate comparison 
between race/ethnicity groups with variables that were significant at p < 0.05 were kept in the 
final model. 
 To evaluate the secondary aim of short-term outcomes, univariate logistic regression 
analyses were carried out to examine the association between exposure (race/ethnicity-
population density group) and outcomes (30-day unplanned readmission, 30-day death, and 90-
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day death).  For ease of comparison, reference group was carried over from the primary outcome.  
Three separate multivariable logistic regressions were fit using backwards stepwise regression 
based on variables that were different at p < 0.20 on univariate comparison between 
race/ethnicity groups with variables that were significant at p < 0.05 kept in the final model.  
Results are reported as odds ratio (OR) or adjusted odds ratio (aOR) with 95% CI and the p-
values reported are for the maximum likelihood estimate.  All statistics were performed using  
SAS software (version 9.4, Cary, NC).  Statistical significance was defined as p < 0.05. 
 
Sensitivity Analysis for Missing Information on Clinical Stage 
 A sensitivity analysis was performed examining the primary study outcome (i.e., timing 
from diagnosis to definitive surgery) stratified by race/ethnicity and population density among 
patients excluded from the main analysis for having missing data on the clinical stage of their 
malignancy.  These groups were compared by whether they received neoadjuvant therapy or 
were direct-to-surgery with their respective groups in the main study analysis.   
 
Ethical Considerations: 
The Institutional Review Board at the University of Massachusetts Medical School 
deemed this study non-human subjects research and exempt from IRB review due to the de-
identified nature of the data. In compliance with the NCDB data use agreement, this study 
suppresses all non-zero counts that are less than ten unless they are in the “missing” or 
“unknown” categories to prevent potential identification of subjects. 
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Chapter 3: Results 
There was a total of 290,015 cases of rectal cancer during the period under study (2004-
2016) (Figure 1).  The study cohort excluded patients with non-adenocarcinoma histology (n = 
35,896),  non-invasive tumor biology (n = 12,091), missing information on clinical stage (n = 
71,555), and stage IV patients (n =3 7,398).  Patients were excluded if they were missing 
information on the exposures of interest (race, ethnicity, or population density, n = 15,772) or the 
outcome (timing to definitive surgery, n = 21,517).  Patients in clinical trials were excluded (n = 
60) because this likely would affect timing of therapy.  Finally, only patients who underwent 
surgical resection of the rectum (i.e., partial or total proctectomy) were included because this 
reflects the oncologic standard-of-care procedure (all other procedures, n = 19,595).  
The final study cohort consisted of 76,131 cases of clinical stage I-III invasive rectal 
adenocarcinoma.  In terms of race/ethnicity, 65,172 were NHWs (85.6%), 6,167 NHBs (8.1%), 
and 4,792 Hispanics (6.3%) and 61,363 patients (80.6%) lived in metropolitan areas and 14,768 
in urban/rural areas. The average age of the study cohort was 62 years old and 38.5% were 
women. 
 
Patient Characteristics According to Race/Ethnicity  
In examining differences in selected characteristics according to race/ethnicity, NHWs  
were significantly older, more likely to have private insurance, receive care at a comprehensive 
community cancer program, be treated at facilities in the Midwest, and to be treated at high 
volume surgical centers than NHBs or Hispanics (Table 1).  In addition, NHWs were 
significantly less likely to live in metropolitan areas, live in areas of the lowest education and 
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income quartiles, and live within 10 miles of the treatment facility.  NHBs had a significantly 
higher proportion of females compared with NHWs and Hispanics. 
 
Timing of Diagnosis to Definitive Surgery 
Timing from diagnosis to definitive surgery was analyzed according to whether patients 
were direct-to-surgery or underwent neoadjuvant therapy.  For those in the direct-to-surgery 
group, the greatest difference in mean time from diagnosis to surgery was 20.3 days (urban/rural 
NHWs, 53.3 days, vs. metropolitan Hispanics, 73.6 days; Table 2).  Among patients receiving 
neoadjuvant therapy, the greatest difference in mean time from diagnosis to surgery was 18.8 
days (urban/rural NHWs, 136.9 days, vs. metropolitan NHBs, 155.7 days). 
 
Timing of Diagnosis to Definitive Surgery in the Direct-to-Surgery Group 
Compared to the reference group, urban/rural NHWs, the average length of time from 
diagnosis to definitive surgery in NHB patients was 14.5 days longer among those living in 
urban/rural areas (95% CI 6.4-22.6) and 13.1 days longer for those living in metropolitan areas 
(95% CI 10.0-16.2; Table 3).  Compared to the same reference group, for Hispanic patients, the 
average time did not signficantly differ in urban/rural areas but was 20.3 days longer for those 
living in metropolitan areas (95% CI 17.0-23.6).  Among NHWs living in metropolitan areas, the 
average time was not significantly different from urban/rural NHWs. 
After adjusting for age, year of diagnosis, insurance status, education level, distance to 
treatment facility, facility type, facility location, facility volume, and clinical stage group, the 
average length of time to surgery in NHB patients was 14.5 days longer for those living in 
urban/rural areas (95% CI 6.6-22.4) and 15.2 days longer for those living in metropolitan areas 
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(95% CI 11.9-18.5) compared to urban/rural NHWs.  For Hispanic patients living in urban/rural 
areas did not significantly differ in time from diagnosis to surgery from urban/rural NHWs; 
however, Hispanics in metropolitan areas did significantly differ from urban/rural NHWs (16.5 
days longer, 95% CI 12.9-20.0).  For the metropolitan NHWs, the average time to surgery was 
4.6 days longer than for urban/rural NHWs (95% CI 2.5-6.7). 
 
Timing of Diagnosis to Definitive Surgery in the Neoadjuvant Therapy Group 
Compared to the reference group, urban/rural NHWs, the average length of time from 
diagnosis to definitive surgery in NHB patients was 14.3 days longer for those living in 
urban/rural areas (95% CI 10.1-18.5) and 18.8 days longer for those living in metropolitan areas 
(95% CI 17.0-20. 6; Table 4).  Compared to the same reference group, for Hispanic patients, the 
average time was 7.7 days longer for those living in urban/rural areas (95% CI 1.8-13.6) and 16.4 
days longer for those living in metropolitan areas (95% CI 14.5-18.3).  For metropolitan NHWs, 
the average time was 3.6 days longer than urban/rural NHWs (95% CI 2.5-4.6). 
After adjusting for age, year of diagnosis, insurance status, education level, distance to 
treatment facility, facility type, location,  and volume, comorbidity status, and clinical stage, the 
average length of time to surgery in NHB patients was 12.7 days longer for those living in 
urban/rural areas (95% CI 8.4-17.0) and 18.1 days longer living in metropolitan areas (95% CI 
16.1-20.0) compared to urban/rural NHWs.  For Hispanic patients, the difference from 
urban/rural NHWs was non-significant in urban/rural areas but significant in metropolitan areas 
(11.8 days longer, 95% CI 9.6-13.9).  For metropolitan NHWs, the average time was 3.7 days 
longer than urban/rural NHWs (95% CI 2.5-4.9). 
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Interaction Between Race/Ethnicity and Population Density 
In direct-to-surgery patients, an interaction term between race/ethnicity group and 
population density was not statistically significant for time from diagnosis to definitive surgery.  
However, in patients receiving neoadjuvant therapy, an interaction term between race/ethnicity 
and population density was statistically significant for time from diagnosis to definitive surgery 
(p = 0.01).  In this model, rural/urban location was associated with a shorter mean time interval 
from diagnosis to definitive surgery in Hispanics (35.9 vs. 40.6 days with metropolitan location).  
However, rural/urban location was associated with a longer mean time interval in NHBs (41.5 
vs. 40.7 days for metropolitan) and in NHWs (33.9 vs. 33.7 days for metropolitan).   
 
Sensitivity Analysis of Excluded Missing Clinical Stage Patients  
Among the 71,555 patients excluded for missing information on the clinical stage of their 
disease, 23,394 patients met all the other inclusion/exclusion criteria and had data regarding the 
receipt of neoadjuvant therapy, which is critical for evaluating timing to definitive surgery.   
In the direct-to-surgery group,  a total of 12,578 patients were excluded for missing data 
on clinical stage, and these patients were compared to the 26,916 patients included in the final 
analysis.  Mean time to surgery in the excluded patients was significantly shorter at 26.2 days 
(95% CI 25.6-26.8) compared to the analysis patients’ mean of 56.7 days (95% CI 56.0-57.4);  
these differences were statistically significant within every race/ethnicity-population density 
group.  Mean time to surgery was as follows for excluded (vs. analysis) patients by race/ethnic-
population density groups: urban/rural NHB 28.9 days (vs. 67.8); metropolitan NHB 28.0 days 
(vs. 66.4); urban/rural Hispanic 18.3 days (vs. 63.9); metropolitan Hispanic 28.9 days (vs. 73.6); 
urban/rural NHW 25.1 days (vs. 53.3); metropolitan NHW 26.3 days (vs. 55.0).  This appeared 
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to be driven by the high proportion of patients who underwent surgery almost immediately after 
diagnosis: 2,340 (18.6%) patients within a day of diagnosis and 3,676 (29.2%) within a week of 
diagnosis. 
In the neoadjuvant group, the 10,816 patients excluded for missing clinical staging were 
compared to the 49,215 patients included in the final analysis.  Mean time to surgery in the 
excluded patients was significantly shorter at 105.0 days (95% CI 104.2-105.8) compared to the 
analysis patients’ mean of 107.1 days (95% CI 106.7-107.4).  When stratified by race/ethnicity-
population density groups, mean time to surgery significantly differed only within the 
metropolitan NHW groups (excluded mean 103.7 vs. analysis mean 106.8 days). 
 
Short-Term Outcomes 
Unplanned readmissions within 30-days of surgical discharge differed between groups 
with the lowest rate observed among rural/urban Hispanics (5.9%) and the highest rate in 
rural/urban NHBs (9.0%, p < 0.001).  The odds of 30-day unplanned readmission were higher for 
urban/rural NHBs (OR 1.36, 95% CI 1.04-1.79) compared to rural/urban NHWs (Table 5).  After 
adjustment for year of diagnosis, sex, insurance, distance to treatment facility, facility region, 
facility volume, and comorbidity status, odds of readmission were still higher for urban NHBs 
(aOR 1.36, 95% CI 1.03-1.79) compared to rural/urban NHWs.  In contrast, odds of 30-day 
unplanned readmission were lower for metropolitan NHWs (OR 0.90, 95% CI 0.83-0.97) 
compared to rural/urban NHWs.  After adjustment for the same clinical and socioeconomic 
factors, odds of readmission were still lower for metropolitan NHW (aOR 0.88, 95% CI 0.80-
0.96). 
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All-cause mortality at 30-days after definitive surgery did not differ between our 
principal study groups with the lowest rate observed in rural/urban Hispanics (0.7%) and the 
highest rate in metropolitan NHBs (1.3%, p = 0.63).  The odds of dying at 30-days were not 
significantly different for any racial/ethnic-population density group when compared to 
rural/urban NHWs.  After adjustment for age, sex, insurance, facility volume, and comorbidity 
status, there were still no significant differences for any racial/ethnic-population density group. 
All-cause mortality at 90-days after definitive surgery differed significantly between 
various comparison groups with the lowest rate observed in metropolitan Hispanics (1.8%) and 
the highest rate in rural/urban NHBs (4.1%, p = 0.003).  The odds of 90-day mortality were 
higher for urban/rural NHBs (OR 1.77, 95% CI 1.16-2.68) compared to rural/urban NHWs.  
After adjustment for age, sex, insurance, facility region, facility volume, comorbidity status, and 
clinical stage, odds were 90-day mortality were still higher compared to rural/urban NHWs with 
increased magnitude (aOR 2.21, 95% CI 1.44-3.41).  Conversely, the odds of dying within the 
first 90 days after definitive surgery were lower for metropolitan Hispanics (OR 0.76, 95% CI 
0.58-0.99; aOR 0.97, 95% 0.73 – 1.28) compared with rural/urban NHWs. 
 
As I  noted earlier, you might want to try to carry out a multivariable adjusted logistic 
regression analysis on all or some of these short-term outcomes and  see if it changes either the 
magnitude or direction of your unadjusted findings.  
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Chapter 4: Discussion 
This study utilized data from the NCDB to evaluate the association of race/ethnicity and 
population density with delays in timing of definitive surgery in patients with resectable rectal 
cancer.  After adjusting for a variety of clinical and socioeconomic factors, over two week delays 
from diagnosis to surgery were seen in the neoadjuvant and direct-to surgery settings for NHB 
patients living in both rural/urban areas and metropolitan areas and Hispanic patients in 
metropolitan areas compared to urban/rural NHW patients.  While 30-day all-cause mortality did 
not differ between groups, NHB patients living in metropolitan and urban/rural areas were at 
geratest risk for dying within 90 days following definitive surgery. 
The World Health Organization defines Social Determinants of Health as “the conditions 
in which people are born, grow, work, live, and age, and the wider set of forces and systems 
shaping the conditions of daily life.”28  A key intent of this study was to begin to deconstruct 
access to care inequalities that arise from beyond a single socioeconomic construct.  Inasmuch,  
we examined race/ethnicity with population density in tandem.  Timing from diagnosis to 
definitive surgery served as a proxy measure in this study for potential access to care disparities.  
To identify which patients have increased vulnerability to access issues that can stem from 
underlying social and economic conditions,29 it is critical to interpret information obtained from 
patients in a larger context, especially using sources of data that are potentially generalizable to 
broader populations, such as the NCDB .   
We found that racial/ethnic minority status was associated with delays in receipt of 
definitive surgery.  These delays persisted after adjusting for other key potentially confounding 
socioeconomic factors that have been previously shown to be linked to survival differences 
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including insurance status,30, 31 education level,32 and facility volume.33  In addition, these delays 
in timing did not seem to worsen with addition of more complex care (i.e., neoadjvuant therapy).  
 While impossible to disentangle the causality of the findings of our observational study,  
our results suggest that the observed delays may lie with initial access rather than coordination of 
care.  Both NHB and Hispanic minority groups experienced care delays in the metropolitan 
setting.  While this may be contrary to our initial thinking that access would be easier with 
increased density of cancer centers, delays among minority patients who live in metropolitan 
settings have been shown in other studies.  A study of colorectal cancer patients in California  
showed that a lower proportion of minority patients used high volume hospitals for colorectal 
cancer care despite a higher proportion living nearby.34  Increased distance and travel time have  
been found in black female breast cancer patients for radiotherapy facility access in both 
Atlanta35 and Detroit36 metropolitan areas.  While a different disease process, these challenges 
with radiotherapy access likely reflect systemic access disparities to onocologic facilities. 
While the focus of our study was patients undergoing surgery to evaluate timing 
differences, it is important to acknowledge that disparities exist throughout the quality of 
oncologic care received as well.  Black race and rurality have been found to be independent 
predictors of who refuses rectal cancer surgery, and this could be a key contributor to survival 
differences observed between races and different population densities.37  Prior studies have  
found a higher odds of inadequate radiation dosing in rectal cancer patients of race other than 
NHW, NHB, Hispanic, Asian-Pacific Islander and those living in rural settings19 and that blacks 
were less likely to receive standard adjuvant therapy.16  Importantly, multiple studies have shown 
that black patients tend to present with higher stages of rectal cancer as well, a key prognostic 
indicator of a worse outcome.14, 38, 39 
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Important future directions of this research include to determine how these combined 
socioeconomic factors contribute to disparities in survival and whether these gaps arise at 
specialist referral stage, patient understanding of time urgency and gravity of disease, lack of 
social and financial support structure, and unequal effects of insurance and scheduling issues.  In 
addition, further examination and identification of other socioeconomic factors that increase 
vulnerability in accessing medical care may be important including age, health literacy, 
psychosocial factors, and the distance to treatment centers.  Finally, it will be important to 
perform qualitative research within at-risk communities and prospective institutional level 
research to determine how best to mitigate these delays in access to care.   
 
Study Strengths and Limitations 
A strength of this study is the joint examination of two key components of socioeconomic 
status, race/ethnicity and population density, which reflects a more comprehensive approach to 
disparities research.  In addition, the large size of this dataset allows for the study of subsets of 
patients, namely urban/rural minority patients, receiving surgical care.  Furthermore, the data 
granularity within the NCDB allows evaluation of timing differences as a proxy measure for care 
access, which has not been captured in other data sets. 
A limitation of this study was our inability to look specifically at rural minority patients 
due to limited sample size in the NCDB population, likely reflecting how NCDB only collects 
data from Commission on Cancer-accredited hospitals that may not include rural patients.  To 
better examine the interplay of rurality and race, utilization of a different database such as SEER 
may be more beneficial.  In addition, since this is an observational study, it was not possible to 
determine the causality of why there was additional time to receipt of definitive surgery in some 
   21
groups of patients; this would need to be conducted on a prospective local level.  Furthermore, 
unmeasured and residual confounding are possible as there are variables not captured in this 
database that could be key to understanding reasons for delay and difficulty with access of care.  
These variables include factors such as health literacy, a more accurate reflection of financial 
liquidity, patients’ support networks, and facility and referral network capacity.  Closer 
examination of these additional factors could be important avenues of future study on an 
institutional and more granular level to improve access for these vulnerable patient populations.  
Finally, a large proportion of the dataset had to be excluded for missing clinical staging 
information.  While a sensitivity analysis was performed to examine the characteristics of these 
patients, it is not clear why excluded direct-to-surgery patients had significantly shorter intervals 
to surgery.  While NCDB lacks an emergency surgery variable, given the proximity of time from 
diagnosis to surgery, likely a large subset of these patients required urgent or emergent surgery 
and did not undergo neoadjuvant therapy or proper staging work-up. 
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Chapter 5: Conclusions 
Minority status and metropolitan living location were associated with delays from 
diagnosis to definitive surgery in patients with resectable rectal cancer that persisted after 
adjusting for other important clinical/socioeconomic factors. Identification of which components 
of socioeconomic determinants of health place patients at increased risk of delays could be 
instrumental to mitigating and actively addressing obstacles to the timely access to care among 
these patients . 
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Table 1: Patient Demographic and Clinical Characteristics According to Race/Ethnicity 
 Non-Hispanic  
Black (n=6,167) 
Hispanic 
(n=4,792) 
Non-Hispanic 
White (n=65,172) 
p-value 
County type    <0.001 
   Metropolitan 5476 (88.8) 4460 (93.1) 51427 (78.9)  
   Urban/Rural 691 (11.2) 332 (7.0) 13745 (21.1)  
Age at diagnosis, years, mean (SD) 60 (12) 59 (13) 62 (13) <0.001 
Year of diagnosis    <0.001 
   2004-2008 1593 (25.8) 1156 (24.1) 17832 (27.4)  
   2009-2012 2143 (34.8) 1566 (32.7) 22336 (34.3)  
   2012-2016 2431 (39.4) 2070 (43.2) 25004 (38.4)  
Sex, male 3584 (58.1) 3045 (63.5) 4023 (61.7) <0.001 
Insurance Status    <0.001 
   Private 2599 (42.1) 1996 (41.7) 32200 (49.4)  
   Government 3031 (49.2) 2157 (45.0) 30282 (46.5)  
   None 445 (7.2) 549 (11.5) 1903 (2.9)  
   Unknown 92 (1.5) 90 (1.9) 787 (1.2)  
Lowest Education Quartile 2513 (40.8) 2568 (53.6) 10403 (16.0) <0.001 
Lowest Income Quartile 2788 (45.2) 1269 (26.5) 9925 (15.2) <0.001 
Distance to Facility    <0.001 
   <10 miles 3770 (61.1) 2864 (59.8) 27844 (42.7)  
   10-50 miles 1944 (31.5) 1532 (32.0) 27919 (42.8)  
   >50 miles 450 (7.3) 392 (8.2) 9346 (14.3)  
Facility Type    <0.001 
  Community Cancer Program 373 (6.4) 357 (8.0) 5608 (8.9)  
  Comprehensive Community Cancer Program 2029 (34.5) 1736 (38.8) 27250 (43.4)  
  Academic/Research Program 2614 (44.5) 1813 (40.5) 21027 (33.5)  
  Integrated Network Cancer Program 862 (14.7) 571 (12.8) 8905 (14.2)  
Facility Location     
  Northeast 891 (14.5) 805 (16.8) 12515 (19.2)  
  South 3463 (56.2) 1643 (34.3) 21029 (32.3)  
  Midwest 1229 (20.0) 450 (9.4) 19535 (30.0)  
  West 295 (4.8) 1579 (33.0) 9711 (14.9)  
Facility Volume (cases/5-year)    <0.001 
  Low (1-11) 536 (8.7) 474 (9.9) 5424 (8.3)  
  Medium (12-28) 1474 (24.0) 1068 (22.3) 14143 (21.8)  
  High (29-412) 4146 (67.4) 3246 (67.8) 45469 (69.9)  
Charlson-Deyo Score    0.005 
   0 4670 (75.7) 3709 (77.4) 50221 (77.1)  
   1 1125 (18.2) 855 (17.8) 11338 (17.4)  
   2 245 (4.0) 157 (3.3) 2591 (4.0)  
   3+ 127 (2.1) 71 (1.5) 1022 (1.6)  
Clinical stage group    <0.001 
   Stage 1 1340 (21.7) 961 (20.1) 15689 (24.1)  
   Stage 2 2174 (35.3) 1577 (32.9) 23575 (36.2)  
   Stage 3 2653 (43.0) 2254 (47.0) 25908 (39.8)  
All values given are n (col%) unless otherwise specified. 
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Table 2: Mean Time in Days from Diagnosis of Rectal Cancer to Definitive Surgery 
 Non-Hispanic Black 
(n=6,167) 
Hispanic 
(n=4,792) 
Non-Hispanic White 
(n=65,172) 
p-
value 
Patient Treatment 
Group 
Rural/Urban 
(n=691) 
Metropolitan 
(n=5,476) 
Rural/Urban 
(n=332) 
Metropolitan 
(n=4,460) 
Rural/Urban 
(n=13,745) 
Metropolitan 
(n=51,427) 
 
Direct-to-Surgery  67.8 (61.7) 66.4 (71.9) 63.9 (60.9) 73.6 (71.2) 53.3 (52.2) 55.0 (55.9) <0.001 
Neoadjuvant 151.2 (52.7) 155.7 (57.1) 144.6 (57.2) 153.3 (49.0) 136.9 (40.5) 140.5 (45.6) <0.001 
All values given are mean (standard deviation).  
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Table 3 –Delay from Diagnosis to Definitive Surgery Among Direct-to-Surgery Patients 
 Univariate Multivariable 
Patient Group Beta-Coefficient 95% CI p-value Beta-Coefficient 95% CI p-value 
NHB       
  Urban/rural 14.5 6.4 – 22.6 <0.001 14.5 6.6 – 22.4 <0.001 
  Metropolitan 13.1 10.0 – 16.2 <0.001 15.2 11.9 – 18.5 <0.001 
Hispanic       
  Urban/rural 10.6 -1.4 – 22.5 0.08 4.4 -7.5 – 16.2 0.47 
  Metropolitan 20.3 17.0 – 23.6 <0.001 16.5 12.9 – 20.0 <0.001 
NHW       
  Urban/rural Ref. Ref. Ref. Ref. Ref. Ref. 
  Metropolitan 1.7 -0.2 – 3.5 0.08 4.6 2.5 – 6.7 <0.001 
 
The multivariable ANCOVA is adjusted for age, year of diagnosis, insurance status, education 
level, distance to treatment facility, facility type, facility location, facility volume, and clinical 
stage group. 
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Table 4 –Delay from Diagnosis to Definitive Surgery Among Neoadjuvant Patients 
 Univariate Multivariable 
Patient Group Beta-Coefficient 95% CI p-value Beta-Coefficient 95% CI p-value 
NHB       
  Urban/rural 14.3 10.1 – 18.4 <0.001 12.7 8.4 – 18.0 <0.001 
  Metropolitan 18.8 17.0 – 20.6 <0.001 18.1 16.1 – 20.0 <0.001 
Hispanic       
  Urban/rural 7.7 1.8 – 13.6 0.01 3.9 -2.1 – 9. 8 0.20 
  Metropolitan 16.4 14.5 – 18.3 <0.001 11.8 9.6 – 13.9 <0.001 
NHW       
  Urban/rural Ref. Ref. Ref. Ref. Ref. Ref. 
  Metropolitan 3.6 2.5 – 4.5 <0.001 3.7 2.5 – 4.9 <0.001 
 
The multivariable ANCOVA is adjusted for age, year of diagnosis, insurance status, education 
level, distance to treatment facility, facility type, facility location, facility volume, comorbidity 
status, and clinical stage group. 
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Table 5 –Short Term Outcomes Stratified by Race/Ethnicity-Population Density Groups 
 Univariate Multivariable 
Patient Group OR 95% CI p-value aOR 95% CI p-value 
30-Day Unplanned Readmission After Discharge 
NHB       
  Urban/rural 1.36 1.04 – 1.79 0.01 1.36 1.03 – 1.79 0.01 
  Metropolitan 1.05 0.93 – 1.18 0.52 0.97 0.85 – 1.11 0.72 
Hispanic       
  Urban/rural 0.85 0.53 – 1.35 0.39 0.87 0.54 – 1.42 0.54 
  Metropolitan 0.95 0.83 – 1.09 0.39 0.95 0.82 – 1.10 0.54 
NHW       
  Urban/rural Ref. Ref. Ref. Ref. Ref. Ref. 
  Metropolitan 0.90 0.83 – 0.97 0.03 0.88 0.80 – 0.96 0.02 
30-Day All-Cause Mortality After Definitive Surgery 
NHB       
  Urban/rural 0.98 0.46 – 2.10 0.83 1.37 0.63 – 2.96 0.59 
  Metropolitan 1.17 0.87 – 1.57 0.14 1.53 1.13 – 2.06 0.09 
Hispanic       
  Urban/rural 0.59 0.15 – 2.39 0.47 0.88 0.21 – 3.58 0.66 
  Metropolitan 0.86 0.60 – 1.23 0.80 1.15 0.80 – 1.66 0.94 
NHW       
  Urban/rural Ref. Ref. Ref. Ref. Ref. Ref. 
  Metropolitan 0.96 0.80 – 1.16 0.70 1.02 0.84 – 1.24 0.46 
90-Day All-Cause Mortality After Definitive Surgery 
NHB       
  Urban/rural 1.77 1.16 – 2.68 0.01 2.21 1.44 – 3.41 0.01 
  Metropolitan 1.21 0.99 – 1.49 0.32 1.51 1.22 – 1.87 0.17 
Hispanic       
  Urban/rural 1.05 0.49 – 2.24 0.89 1.42 0.65 – 3.07 0.78 
  Metropolitan 0.76 0.58 – 0.99 0.004 0.97 0.73 – 1.28 0.02 
NHW       
  Urban/rural Ref. Ref. Ref. Ref. Ref. Ref. 
  Metropolitan 1.00 0.88 – 1.14 0.27 1.06 0.92 – 1.22 0.02 
 
The multivariable logistic regression for the 30-day unplanned readmission after discharge 
outcome was adjusted for year of diagnosis, sex, insurance, distance to treatment facility, facility 
region, facility volume, and comorbidity status. 
 
The multivariable logistic regression for the 30-day all-cause mortality outcome after definitive 
surgery was adjusted for age, sex, insurance, facility volume, and comorbidity status. 
 
The multivariable logistic regression for the 90-day all-cause mortality outcome after definitive 
surgery was adjusted for age, sex, insurance, facility region, facility volume, comorbidity status, 
and clinical stage. 
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Figures 
Figure 1—Study Flow Diagram 
 
 
